Literature DB >> 23231788

Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.

Setareh Moghadasi1, Nandy Hofland, Joyce N Wouts, Frans B L Hogervorst, Juul T Wijnen, Maaike P G Vreeswijk, Christi J van Asperen.   

Abstract

BACKGROUND: Nearly 15% of BRCA1 and BRCA2 DNA tests lead to the identification of Variants of Uncertain Significance (VUS). VUS are classified in the Netherlands according to the Bell system and it is current practice that class III VUS are communicated to counsellees, but not class II or lower VUS. Our aims were to investigate the utility of in silico characteristics in the classification of VUS and whether initial VUS classifications justify differences in communication protocols during counselling.
METHODS: We classified 88 missense VUS in BRCA1 and BRCA2 on the basis of an in silico analysis and compared the classification of a subset of 60 VUS of which additional information including family, genetic and tumour data was available.
RESULTS: VUS allocated to class III more frequently showed in silico indications of a deleterious effect than class II VUS. Of the 46 VUS assigned to class II by in silico analysis alone, nearly half were eventually recategorised as class I and 10% as class III when additional information was included.
CONCLUSIONS: As in silico analysis alone is not always sufficient to unambiguously assign VUS to either class II or class III, we would argue that the prospect of obtaining additional information from a family should be given more weight during the decision process preceding the communication of a VUS test result. Research initiatives such as the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), which strive to combine diverse sources of information, will be valuable in aiding a definitive classification of a VUS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23231788     DOI: 10.1136/jmedgenet-2012-100961

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

Review 1.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

Authors:  D M Eccles; G Mitchell; A N A Monteiro; R Schmutzler; F J Couch; A B Spurdle; E B Gómez-García
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

2.  The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.

Authors:  Fred H Menko; Jacqueline A Ter Stege; Lizet E van der Kolk; Kiki N Jeanson; Winnie Schats; Daoud Ait Moha; Eveline M A Bleiker
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

3.  Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2.

Authors:  Raghad Aljarf; Mengyuan Shen; Douglas E V Pires; David B Ascher
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

4.  Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results.

Authors:  Hyung Seok Park; Seo-Jin Park; Jee Ye Kim; Sanghwa Kim; Jaegyu Ryu; Joohyuk Sohn; Seho Park; Gun Min Kim; In Sik Hwang; Jong-Rak Choi; Seung Il Kim
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

5.  Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study.

Authors:  Kah Nyin Lai; Weang Kee Ho; In Nee Kang; Peter Choon Eng Kang; Sze Yee Phuah; Shivaani Mariapun; Cheng-Har Yip; Nur Aishah Mohd Taib; Soo-Hwang Teo
Journal:  BMC Cancer       Date:  2017-02-22       Impact factor: 4.430

6.  BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.

Authors:  F Z Francies; T Wainstein; K De Leeneer; A Cairns; M Murdoch; S Nietz; H Cubasch; B Poppe; T Van Maerken; B Crombez; I Coene; R Kerr; J P Slabbert; A Vral; A Krause; A Baeyens; K B M Claes
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430

Review 7.  Finding all BRCA pathogenic mutation carriers: best practice models.

Authors:  Nicoline Hoogerbrugge; Marjolijn Cj Jongmans
Journal:  Eur J Hum Genet       Date:  2016-09       Impact factor: 4.246

8.  Family Studies for Classification of Variants of Uncertain Classification: Current Laboratory Clinical Practice and a New Web-Based Educational Tool.

Authors:  Lauren T Garrett; Nathan Hickman; Angela Jacobson; Robin L Bennett; Laura M Amendola; Elisabeth A Rosenthal; Brian H Shirts
Journal:  J Genet Couns       Date:  2016-07-16       Impact factor: 2.537

9.  Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.

Authors:  Hiroshi Nakagomi; Hitoshi Mochizuki; Masayuki Inoue; Yosuke Hirotsu; Kenji Amemiya; Ikuko Sakamoto; Satoko Nakagomi; Takeo Kubota; Masao Omata
Journal:  Cancer Sci       Date:  2018-01-17       Impact factor: 6.716

10.  Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.

Authors:  Corinna Ernst; Eric Hahnen; Christoph Engel; Michael Nothnagel; Jonas Weber; Rita K Schmutzler; Jan Hauke
Journal:  BMC Med Genomics       Date:  2018-03-27       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.